Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119 (Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients

Trial Profile

Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119 (Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs Alpha galactosidase (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions
  • Sponsors GC Pharma; Green Cross
  • Most Recent Events

    • 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
    • 26 Aug 2016 Korean registry reports trial status as recruiting. Kept status as per NCT as status information not found on company website.
    • 23 Jun 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top